SKYCLARYS®

Hold Company

Biogen

Learn More

Dosage and Administration

CAPSULE;ORAL

Specification

50MG

Indication

Skyclarys® is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

Use

Instructions for Use

API

OMAVELOXOLONE

API Structure

We Supply

OMAVELOXOLONE

Drug Patent

Patent No	Expiration Date
11091430	2029/4/20
11919838	2029/4/20
8124799	2029/12/3
8440854	2029/4/20
8993640	2033/4/24
9670147	2029/4/20
9701709	2033/4/24

API Patent

Patent No	Expiration Date
11091430	2029/4/20
11919838	2029/4/20
8124799	2029/12/3
8440854	2029/4/20
9670147	2029/4/20

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.